Moderna Rises 4%

Shares of biotechnology company Moderna, Inc. (MRNA) are rising 4 percent on Tuesday's trading after the company announced that it has received approval from the Ministry of Health, Labour and Welfare or MHLW in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 (Spikevax Bivalent Original/Omicron BA.4-5) in adults aged 18 years and above.

Spikevax Bivalent Original/Omicron BA.4-5 contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant BA.4-5.

Currently at $156.39, the stock has traded between $115.03 and $376.65 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT